![conference banner](/images/conference-banner.jpeg)
Abstract
Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Current Pharmaceutical Design
Title: Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Volume: 16 Issue: 27
Author(s): M. A. Lawson, J. Ashcroft and P. I. Croucher
Affiliation:
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Abstract: Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Export Options
About this article
Cite this article as:
A. Lawson M., Ashcroft J. and I. Croucher P., Bisphosphonate Therapy in the Treatment of Multiple Myeloma, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563608
DOI https://dx.doi.org/10.2174/138161210793563608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Letters in Drug Design & Discovery The Value of Low-dose Prospective Dual-energy Computed Tomography with Iodine Mapping in the Diagnosis of Gastric Cancer
Current Medical Imaging The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Potential Therapeutic Strategies to Combat HCC
Current Molecular Pharmacology Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents DNA Vaccines to Improve Immunogenicity and Effectiveness in Cancer Vaccinations: Advancement and Developments
Current Gene Therapy